Ethics of international research: What does responsiveness mean?

Virtual Mentor

Volumn 8, Issue 4, 2006, Pages 235-240

  Grady, Christine ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85009083693     PISSN: 19377010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Wertheimer A. Exploitation. Princeton, NJ: Princeton University Press; 1996.
2. Macklin R. Avoiding exploitation. In: Double Standards in Medical Research in Developing Countries. Cambridge, UK: Cambridge University Press; 2004:99-129.
3. National Bioethics Advisory Commission. Ethical and Policy Issues in International Research: Clinical trials in Developing Countries. Vol. I. Bethesda, Md: National Bioethics Advisory Commission; 2001. Available at: http://www.bioethics.gov/reports/past_commissions/nbac_international.pdf Accessed March 2, 2006.
4. US Code of Federal Regulations. Public welfare. Protection of human subjects. 45 CFR 46 (1991).
5. Emanuel E, Wendler D, Grady C. What makes clinical research ethical? JAMA. 2000;283:2701-2711.
6. Emanuel E, Wendler D, Killen J, Grady C. What makes clinical research in developing countries ethical? The benchmarks of ethical research. J Infect Dis. 2004;189:930-937.
7. The budget for international research of the National Institute of Allergy and Infectious Diseases, the NIH institute with the largest international portfolio, increased fourfold from approximately $100 million in 2000 to $400 million in the 2006 President’s Budget. Information courtesy of Office of Financial Management. NIAID/NIH. Bethesda, Md; 2006. The Bill and Melinda Gates Foundation has spent more than $9 billion on global health since its inception in 2000, and part of their portfolio is research. Available at: http://www.gatesfoundation.org/MediaCenter/FactSheet/. Accessed February 20, 2006.
8. Getz K. A swift predominance of ex-US sites. Applied Clinical Trials. Available at: http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=261633. Accessed March 7, 2006.
9. Macklin R. Double Standards in Medical Research in Developing Countries. Cambridge, UK: Cambridge University Press; 2004:1-31.
10. Nuffield Council on Bioethics. The Ethics of Research Related to Healthcare in Developing Countries. London, UK: Nuffield Council on Bioethics; 2002. Available at: http://www.nuffieldbioethics.org/go/print/ourwork/developingcountries/introduction. Accessed February 28, 2006.
11. Council for International Organizations of Medical Sciences. CIOMS International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva 2002. Available at: http://www.cioms.ch/frame_guidelines_nov_2002.htm. Accessed March 30, 2006.
12. World Medical Association. Declaration of Helsinki, Ethical Principles for Medical Research involving Human Subjects. Principle 19. Available at: http://www.wma.net/e/ethicsunit/helsinki.htm. Accessed February 20, 2006.
13. Macklin R. After Helsinki: unresolved issues in international research. Kennedy Inst Ethics J. 2001; 11:17-36.
14. Shapiro H, Meslin E. Ethical issues in the design and conduct of clinical trials in developing countries. N Engl J Med. 2001;345:139-142.
15. Participants in the 2001 Conference on Ethical Issues of Research in Developing Countries. Fair benefits for research in developing countries. Science. 2002;298:2133-2134.
16. Participants in the 2001 Conference on Ethical Issues of Research in Developing Countries. Moral standards for research in developing countries: from reasonable availability to fair benefits. Hastings Cent Rep. 2004;34:17-27.
17. Kass N, Hyder A. Attitudes and experiences of U.S. and developing country investigators regarding human subjects regulations. In: Ethical and Policy Issues in International Research: Clinical Trials in Developing Countries. Volume II. Washington, DC: National Bioethics Advisory Commission; 2001:B-38-B-39.
18. London A. Justice and the human development approach to international research. Hastings Cent Rep. 2005;35:24-37.